Research Topics
| R S McIntyreSummaryAffiliation: Centre for Addiction and Mental Health Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Acute treatment of patients with bipolar mixed episodesRoger S McIntyre
Department of Psychiatry, University of Toronto, and the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
J Clin Psychiatry 69:e10. 2008..As more medications become available in the treatment of bipolar disorder, algorithms can help clinicians make the appropriate treatment choices by offering recommendations for sequencing agents...
Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalitiesR S McIntyre
Centre for Addiction and Mental Health, Clarke Site, Mood and Anxiety Disorders Program, 250 College Street, Toronto, ON M5T 1R8
Can J Psychiatry 46:273-81. 2001..To review published and nonpublished literature describing changes in weight, glucose homeostasis, and lipid milieu with antipsychotics...
Lithium revisitedR S McIntyre
Bipolar Clinic, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T 1R8
Can J Psychiatry 46:322-7. 2001..To review lithium's utility in the treatment of mood disorders...
Mechanisms of antipsychotic-induced weight gainR S McIntyre
Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Ontario, Canada
J Clin Psychiatry 62:23-9. 2001..Research success in this area may invite novel prevention strategies and hint at potential mechanisms of antipsychotic drug action...
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisitedRoger S McIntyre
Mood Disorders Program, Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Ontario, Canada
J Clin Psychiatry 63:15-20. 2002..Most of their adverse effects can be avoided by slow titration toward the recommended doses. In contrast to carbamazepine and valproic acid, topiramate may be associated with weight loss...
Assessing full remissionRoger McIntyre
Mood and Anxiety Disorders Program, Department of Psychiatry, University of Toronto, Toronto, Ont
J Psychiatry Neurosci 27:235-9. 2002..A score of 3 or less on the Toronto HAM-D7 was found to correlate with the 17-item HAM-D definition of full remission (i.e., score of 7 or less)...
Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind studyRoger S McIntyre
Department of Psychiatry, University of Toronto, Mood and Anxiety Disorders Program, Center for Addiction and Mental Health, Clarke Site, Ontario, Canada
Bipolar Disord 4:207-13. 2002....
Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzleV S Basile
Centre for Addiction and Mental Health, Clarke Division, University of Toronto, Ontario, Canada
J Clin Psychiatry 62:45-66. 2001....
The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorderC Y Yim
Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
Eur Psychiatry 27:223-8. 2012..This sub-group post-hoc analysis preliminarily explores and examines the association between overweight/obesity and cognitive function in euthymic individuals with bipolar disorder...
The effect of bipolar I disorder and major depressive disorder on workforce functionR S McIntyre
Department of Psychiatry, University of Toronto, ON, Canada
Chronic Dis Can 28:84-91. 2008..5 to 0.9). The data herein underscore the pernicious effect of BD on workforce function, and suggest that opportunistic screening for BD in all individuals utilizing employment assistance programs for depression might be warranted...
Measuring depressive symptoms in the naturalistic primary-care settingR S McIntyre
Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Int J Clin Pract 61:1278-82. 2007..A quantifiable critical objective in the management of depression is to achieve and sustain full symptomatic remission. The HAMD-7 is a depression metric validated in both tertiary and primary-care settings...
Differentiating bipolar disorders from major depressive disorders: treatment implicationsDavid J Muzina
Cleveland Clinic Neurological Institute, Psychiatry and Psychology, Cleveland, OH 44195, USA
Ann Clin Psychiatry 19:305-12. 2007..Bipolar disorder is a highly prevalent mood disorder, frequently misdiagnosed as unipolar major depressive disorder...
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007Lakshmi N Yatham
Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, Vancouver, BC, Canada
Bipolar Disord 8:721-39. 2006..The importance of comorbid psychiatric and medical conditions cannot be understated, and this update provides an expanded look at the prevalence, impact and management of comorbid conditions in patients with bipolar disorder...
Improving outcomes in depression: a focus on somatic symptomsRoger S McIntyre
Department of Psychiatry, University of Toronto, Toronto, ON, Canada
J Psychosom Res 60:279-82. 2006..It is hypothesized that somatic symptom alleviation is a significant predictor of overall outcome in depressed primary care patients...
Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptomsRoger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
J Affect Disord 100:S5-14. 2007..This post-hoc analysis aims to extend our understanding of quetiapine's antimanic efficacy by evaluating its therapeutic effect across the full spectrum of manic symptoms...
Residual anxiety symptoms in depressed primary care patientsRoger S McIntyre
University of Toronto, Toronto, Ontario, Canada
J Psychiatr Pract 13:125-8. 2007..The goal of this study was to characterize the burden of anxiety among residual depressive symptoms in naturalistic primary care settings...
Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-beingRoger S McIntyre
Department of Psychiatry and Pharmacology, University of Toronto, Ontario
Can J Psychiatry 51:274-80. 2006..We further aimed to examine the likelihood of an association between obesity and MD, while controlling for the influence of sociodemographic variables...
Maintenance treatment in bipolar disorder: a focus on aripiprazoleRoger S McIntyre
University of Toronto, Department of Psychiatry, Department of Pharmacology, Toronto, ON, Canada
Expert Rev Neurother 7:919-25. 2007..This article provides a succinct review of treatments approved by the US FDA for maintenance in bipolar disorders, with a focus on the most recently approved atypical antipsychotic, aripiprazole...
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placeboPaul E Keck
Psychopharmacology Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0559, USA
J Clin Psychiatry 68:1480-91. 2007..Efficacy and tolerability of aripiprazole for relapse prevention in bipolar I disorder was, therefore, evaluated for 100 weeks...
Validity of conclusions about quetiapineRoger S McIntyre
Am J Health Syst Pharm 65:114-5; author reply 115-6. 2008
Bipolar disorder and suicide: research synthesis and clinical translationRoger S McIntyre
Department of Psychiatry and Pharmacology, University of Toronto, Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street, Toronto, Ontario M5T 2S8, Canada
Curr Psychiatry Rep 10:66-72. 2008..A nascent database suggests that adjunctive psychosocial interventions may further reduce suicide risk in bipolar individuals...
Bipolar depression: trial-based insights to guide patient careDavid E Kemp
Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio, USA
Dialogues Clin Neurosci 10:181-92. 2008..A pragmatic clinical approach is presented for management of the depressed phase of bipolar disorder...
Open-label adjunctive topiramate in the treatment of unstable bipolar disorderRoger S McIntyre
Mood Disorders Psychoparmacology Unit, University Health Network, Toronto, Ontario
Can J Psychiatry 50:415-22. 2005..To assess open-label adjunctive topiramate in the treatment of outpatients with unstable bipolar disorder (BD)...
Antidepressant augmentation with raloxifeneSophie Grigoriadis
J Clin Psychopharmacol 25:96-8. 2005
The human cost of not achieving full remission in depressionRoger S McIntyre
Department of Psychiatry, University of Toronto, Ontario
Can J Psychiatry 49:10S-16S. 2004....
Antipsychotic-induced weight gain: bipolar disorder and leptinRoger S McIntyre
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
J Clin Psychopharmacol 23:323-7. 2003..05). The temporal association between weight increase and leptin changes does not support the notion that leptin is a primary promoter of antipsychotic-induced weight gain; however, a secondary perpetuating role cannot be ruled out...
Treating bipolar disorder. Evidence-based guidelines for family medicineRoger S McIntyre
Department of Psychiatry, University of Toronto, Ont
Can Fam Physician 50:388-94. 2004..To provide an evidence-based summary of medications commonly used for bipolar disorders and a practical approach to managing bipolar disorders in the office...
An approach to managing depression. Defining and measuring outcomesAtul Khullar
Department of Psychiatry, University of Alberta, Edmonton
Can Fam Physician 50:1374-80. 2004..The 7-item Hamilton Depression Rating Scale can assist clinicians in determining when full remission has occurred...
What to do if an initial antidepressant fails?Roger S McIntyre
Department of Psychiatry, University of Toronto, Ont
Can Fam Physician 49:449-57. 2003..To provide family physicians with practical ways of managing depressed patients responding insufficiently to initial antidepressant treatment...
Comorbidity in bipolar disorder: a framework for rational treatment selectionRoger S McIntyre
Mood Disorder Psychopharmacology Unit, University of Toronto, University Health Network Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario M5T 2S9, Canada
Hum Psychopharmacol 19:369-86. 2004..This schema should be further informed by the treatment data for comorbid and accessory conditions. The authors propose a schema to provide the impetus for further work in the area...
The antidepressant effects of risperidone and olanzapine in bipolar disorderRoger S McIntyre
Department of Psychiatry, University of Toronto, Ontario
Can J Clin Pharmacol 11:e218-26. 2004..To describe the antidepressant effectiveness of olanzapine and risperidone and compare their tolerability when employed adjunctively in bipolar I/II disorder...
Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorderRoger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario M5T 1R8, Canada
J Clin Psychiatry 66:28-36. 2005..This article reviews relevant adverse events attributable to the use of atypical antipsychotic agents, with particular consideration of the bipolar disorder population...
The hepatic safety profile of duloxetine: a reviewRoger S McIntyre
University Health Network, Mood Disorders Psychopharmacology Unit, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
Expert Opin Drug Metab Toxicol 4:281-5. 2008..Hepatotoxicity related to the use of duloxetine resulted in rewording of the US product insert...
Editorial: sharpening the focus in mood disorders: from disease models to individualized measurement-based careRoger S McIntyre
Ann Clin Psychiatry 19:213-4. 2007
Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?Roger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
Ann Clin Psychiatry 19:257-64. 2007..A nascent explanatory theory regarding the pathophysiology of major depressive disorder posits that alterations in metabolic networks (e.g., insulin and glucocorticoid signaling) mediate allostasis...
Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescentsRoger S McIntyre
Department of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada
Arch Pediatr Adolesc Med 162:929-35. 2008..To identify factors associated with incident cardiovascular events and metabolic disturbance in children and adolescents treated with antipsychotics...
Comparing features of bipolar disorder to major depressive disorder in a tertiary mood disorders clinicRoger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
Ann Clin Psychiatry 19:313-7. 2007..We sought to describe features that distinguish individuals with bipolar disorder from major depressive disorder...
Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunitiesRoger S McIntyre
Department of Psychiatry and Pharmacology, University of Toronto, ON, Canada
Dialogues Clin Neurosci 10:203-13. 2008..Subphenotyping bipolar disorder as a function of comorbidity and temporality of onset may provide an opportunity for refining disease pathophysiological models and developing innovative disease-modifying therapies...
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effectsSidney H Kennedy
Centre for Addiction and Mental Health, and the Department of Psychiatry, University of Toronto, Ontario, Canada
J Clin Psychiatry 63:181-6. 2002..CONCLUSION: Bupropion had an effect on the pharmacokinetics of venlafaxine but not those of the SSRIs. Further investigation of combination treatments under randomized, double-blind conditions is recommended...
Bipolar depression: best practices for the outpatientPaul E Keck
Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
CNS Spectr 12:1-14. 2007..Two case studies are presented to elucidate the best practices for the varying clinical states of bipolar disorder...
Assessing the prevalence of depression among individuals with diabetes in a Medicaid managed-care programLinda S Kahn
State University of New York at Buffalo, USA
Int J Psychiatry Med 38:13-29. 2008....
Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorderJakub Z Konarski
Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
Bipolar Disord 10:1-37. 2008..Patient and methodological variability complicates the comparison of neuroimaging study results and limits heuristic model development and a biologically-based diagnostic schema...
Valproate, bipolar disorder and polycystic ovarian syndromeRoger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
Bipolar Disord 5:28-35. 2003..Recent data suggest that valproic acid, a commonly prescribed mood stabilizer, may be associated with polycystic ovarian syndrome (PCOS). This adverse event has not been systematically studied in bipolar disorder...
Considering wellness in managing patients with bipolar disorderRoger S McIntyre
University of Toronto, Toronto, Canada
CNS Spectr 13:7-8. 2008
Antipsychotic drugs and diabetesRoger S McIntyre
CMAJ 168:673. 2003
Anxiety disorders and bipolar disorder: a reviewRoger S McIntyre
Department of Psychiatry and Pharmacology, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, Canada
Bipolar Disord 8:665-76. 2006..Taken together, a compelling basis emerges for prioritizing the identification and management of anxiety symptomatology in the BPD population...
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challengesW Wolfgang Fleischhacker
Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria
J Clin Psychiatry 69:514-9. 2008....
Adverse events in children and adolescents treated with antipsychotic medicationsJeanette M Jerrell
Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, South Carolina 29203, USA
Hum Psychopharmacol 23:283-90. 2008..To report the odds of developing adverse events associated with antipsychotic treatment among children and adolescents...
Substance use disorders and overweight/obesity in bipolar I disorder: preliminary evidence for competing addictionsRoger S McIntyre
Department of Psychiatry, University of Toronto, Ontario, Canada
J Clin Psychiatry 68:1352-7. 2007..This investigation was undertaken to explore the relationship between alcohol/illicit drug dependence and overweight/obesity in individuals with bipolar I disorder...
Reboxetine: a preliminary report on its use through the Special Access ProgramSidney H Kennedy
University Health Network, Department of Psychiatry, University of Toronto, Toronto, Ont
J Psychiatry Neurosci 27:418-22. 2002..To describe the effectiveness and tolerability of reboxetine under Special Access Program conditions in Canada in a group of patients with refractory depressive disorders...
Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?Jakub Z Konarski
Institute of Medical Science, University of Toronto, Canada
J Psychiatry Neurosci 30:178-86. 2005..The available evidence suggests that a functional role for the cerebellum should be considered in future neuropsychiatric studies...
Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunitiesRoger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, 399 Bathurst Street Toronto, ON, M5T 2S8, Canada
Expert Opin Pharmacother 7:1305-21. 2006..Antidiabetic treatments, which maintain euglycaemia, hold promise as potent and clinically significant therapeutic interventions for several neuropsychiatric disorders...
The effect of antidepressants on lipid homeostasis: a cardiac safety concern?Roger S McIntyre
University of Toronto, Department of Psychiatry, Toronto, ON, Canada
Expert Opin Drug Saf 5:523-37. 2006..The authors sought to summarise and synthesise results from investigations which report on the effect of antidepressants on serum lipid homeostasis...
The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanismsRoger S McIntyre
University of Toronto, Department of Psychiatry, University Health Network, 399 Bathurst Street, Toronto, ON, M5T 2S8, Canada
Expert Opin Drug Saf 5:157-68. 2006..To synthesise results from investigations reporting on the effect of antidepressants on glucose-insulin homeostasis...
Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scaleRoger S McIntyre
University of Toronto, Toronto, Ont
CMAJ 173:1327-34. 2005..We evaluated a 7-item abbreviated version (HAMD-7) of the 17-item Hamilton Depression Rating Scale (HAMD-17) in a randomized controlled clinical trial of patients with major depressive disorder being cared for in primary care settings...
Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorderChun Xu
Laboratory of Cellular and Molecular Pathophysiology, Centre for Addiction and Mental Health, University of Toronto, 150 College Street, Toronto, Ontario, Canada M5T 1R8
Am J Med Genet B Neuropsychiatr Genet 141:36-43. 2006..These findings suggest genetic variants of the TRPM2 gene increase risk for BD and support the notion that TRPM2 may be involved in the pathophysiology of BD...
Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trialRoger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Canada
Eur Neuropsychopharmacol 15:573-85. 2005..The primary efficacy outcome variable was change from baseline to Day 21 in Young Mania Rating Scale (YMRS) score...
Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptomsRoger S McIntyre
Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Expert Opin Pharmacother 6:707-13. 2005..Pharmacoeconomic and cost-impact modelling analyses should be reformulated to consider duloxetine's symptom-alleviating effect on the somatic dimension of depressive illness...
Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationshipRoger S McIntyre
University Health Network, and Department of Psychiatry, University of Toronto, Toronto, Ont
CMAJ 172:57-9. 2005
Bipolar disorder: a national health concernRoger S McIntyre
University Health Network, Edith Cavell Wing 3D 003, 399 Bathurst St, M5T 2S8, Ontario, Canada
CNS Spectr 9:6-15. 2004....
Relationship between regional brain metabolism, illness severity and age in depressed subjectsJakub Z Konarski
Institute of Medical Science, University of Toronto, Toronto, ON, Canada
Psychiatry Res 155:203-10. 2007..The age-dependent changes documented herein may influence the distinct clinical presentation and treatment response described in older-age depression...
A preclinical and clinical rationale for quetiapine in mood syndromesRoger S McIntyre
University of Toronto, Department of Psychiatry, Toronto, ON, Canada
Expert Opin Pharmacother 8:1211-9. 2007..The in vitro pharmacodynamic profile of quetiapine is predictive of antidepressant activity in mood syndromes. Available clinical evidence has established quetiapine as an effective monotherapy in bipolar depression...
Medical comorbidity in bipolar disorder: re-prioritizing unmet needsRoger S McIntyre
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
Curr Opin Psychiatry 20:406-16. 2007..The aim of this review is to synthesize results from extant investigations which report on the co-occurrence of bipolar disorder and medical comorbidity...
Aripiprazole: pharmacology and evidence in bipolar disorderRoger S McIntyre
Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Expert Opin Pharmacother 8:1001-9. 2007..Aripiprazole constitutes an alternative mood-stabilizing pharmacologic avenue in bipolar disorder; its comparative efficacy in long-term recurrence prevention and bipolar depression is a future research vista...
Predictors of self-reported antidepressant adherenceTara A Burra
Faculty of Medicine, University of Toronto, Ontario, Canada
Behav Med 32:127-34. 2007..Clinicians should be cognizant of this complexity and address not only issues related to medication efficacy and tolerability, but also social mediators and health beliefs when prescribing antidepressants...
Problem gambling in bipolar disorder: results from the Canadian Community Health SurveyRoger S McIntyre
Department of Psychiatry, University of Toronto, Toronto, ON, Canada
J Affect Disord 102:27-34. 2007..This investigation was undertaken to explore the prevalence and associated features of problem gambling amongst individuals with bipolar I disorder...
Sex differences in antidepressant response in a Canadian primary-care sampleSophie Grigoriadis
J Clin Psychopharmacol 27:95-8. 2007
Measurable outcomes in psychiatric disorders: remission as a marker of wellnessRoger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, Ontario, Canada
Clin Ther 28:1882-91. 2006..Collectively, they are associated with significant morbidity, mortality, and economic cost. Wellness is the optimal outcome in the management of chronic medical and psychiatric disorders...
Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implicationsRoger S McIntyre
Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
Ann Clin Psychiatry 17:83-93. 2005..Preliminary investigations indicate that patients who suffer from BD with comorbid DM have a more severe course and outcome, lower quality of life, higher prevalence of medical comorbidity and higher cost of illness...
